Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of NS-161 in Healthy Female Subjects
jRCT2071220066Phase 1Completed
- Sponsor
- Nippon Shinyaku
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NS-161 (5 arms), sponsored by Nippon Shinyaku. Primary endpoints: Primary: Pharmacokinetics of NS-161, Primary: Safety of NS-161 and 1 more. Started Nov 2022; status: completed.
02
Drugs
NS-161
Beyond the preview
Go deeper on jRCT2071220066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220066.